tradingkey.logo

abt

ABT

133.240USD

-0.759-0.57%
종가 05/09, 16:00ET시세는 15분 지연됩니다
231.82B시가총액
17.30P/E TTM

abt

133.240

-0.759-0.57%
자세한 내용은 Abbott Laboratories 회사
Abbott Laboratories is a global healthcare company. The Company’s principal business is the discovery, development, manufacture, and sale of a broad and diversified line of healthcare products. Its segments include Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. Established Pharmaceutical Products segment is engaged in the international sales of a broad line of branded generic pharmaceutical products. Diagnostic Products segment is involved in the worldwide sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. Nutritional Products segment is engaged in the worldwide sales of a broad line of adult and pediatric nutritional products. Medical Devices segment is involved in the worldwide sales of rhythm management, electrophysiology, heart failure, vascular, structural heart, neuromodulation and diabetes care products. It serves people in more than 160 countries.
회사 정보
회사 코드ABT
회사 이름Abbott Laboratories
상장일Mar 01, 1937
설립일1900
CEOMr. Robert B. Ford
직원 수114000
유형Ordinary Share
회계 연도 종료Mar 01
주소100 Abbott Park Road
도시ABBOTT PARK
증권 거래소NYSE Consolidated
국가United States of America
우편 번호60064-3500
전화12246676100
웹사이트https://www.abbott.com
회사 코드ABT
상장일Mar 01, 1937
설립일1900
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.88K
-1.63%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
56.91K
+44.72%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
+4.17%
Ms. Nancy Mckinstry
Ms. Nancy Mckinstry
Lead Independent Director
Lead Independent Director
38.72K
+4.41%
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
34.06K
-2.76%
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.88K
-1.63%
수익 분석
통화: USD업데이트 시간: Sun, Apr 6
통화: USD업데이트 시간: Sun, Apr 6
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
사업별USD
이름
수익
비율
Diabetes Care
6.80B
16.22%
Core Laboratory
5.24B
12.48%
Adult Nutritionals
4.39B
10.46%
Pediatric Nutritionals
4.02B
9.59%
Key Emerging Markets
3.86B
9.20%
Other
17.64B
42.05%
지역별USD
이름
수익
비율
United States
16.32B
38.91%
All other Countries
14.85B
35.39%
Germany
2.54B
6.05%
China
2.11B
5.04%
India
1.82B
4.33%
Other
4.31B
10.28%
사업별
지역별
사업별USD
이름
수익
비율
Diabetes Care
6.80B
16.22%
Core Laboratory
5.24B
12.48%
Adult Nutritionals
4.39B
10.46%
Pediatric Nutritionals
4.02B
9.59%
Key Emerging Markets
3.86B
9.20%
Other
17.64B
42.05%
주주
업데이트 시간: Sun, Feb 9
업데이트 시간: Sun, Feb 9
주주 통계
유형
주주 통계
주주
비율
The Vanguard Group, Inc.
9.72%
BlackRock Institutional Trust Company, N.A.
5.05%
State Street Global Advisors (US)
4.44%
Capital International Investors
3.91%
Capital Research Global Investors
3.11%
Other
73.78%
주주 통계
주주
비율
The Vanguard Group, Inc.
9.72%
BlackRock Institutional Trust Company, N.A.
5.05%
State Street Global Advisors (US)
4.44%
Capital International Investors
3.91%
Capital Research Global Investors
3.11%
Other
73.78%
유형
주주
비율
Investment Advisor
35.72%
Investment Advisor/Hedge Fund
32.69%
Research Firm
3.26%
Pension Fund
2.25%
Bank and Trust
2.15%
Sovereign Wealth Fund
1.31%
Insurance Company
1.01%
Hedge Fund
0.88%
Individual Investor
0.48%
Other
20.25%
기관 주식 보유
업데이트 시간: Sun, Jan 19
업데이트 시간: Sun, Jan 19
보고 기간
기관 수
보유 주식
비율
변동
2025Q1
4562
1.39B
80.14%
+12.65M
2024Q4
4535
1.39B
80.22%
+15.89M
2024Q3
4391
1.36B
78.29%
-11.85M
2024Q2
4400
1.36B
78.24%
-7.03M
2024Q1
4402
1.35B
77.67%
-9.71M
2023Q4
4429
1.35B
77.56%
-11.05M
2023Q3
4298
1.34B
77.39%
-25.33M
2023Q2
4297
1.35B
77.60%
-13.55M
2023Q1
4281
1.35B
77.46%
-8.61M
2022Q4
4258
1.34B
76.84%
-15.37M
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
The Vanguard Group, Inc.
167.89M
9.68%
+762.54K
+0.46%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
87.07M
5.02%
+811.85K
+0.94%
Dec 31, 2024
State Street Global Advisors (US)
77.17M
4.45%
+447.25K
+0.58%
Dec 31, 2024
Capital International Investors
67.97M
3.92%
+2.23M
+3.39%
Dec 31, 2024
Capital Research Global Investors
54.10M
3.12%
+795.07K
+1.49%
Dec 31, 2024
Geode Capital Management, L.L.C.
35.67M
2.06%
+765.64K
+2.19%
Dec 31, 2024
Wellington Management Company, LLP
26.39M
1.52%
+581.33K
+2.25%
Dec 31, 2024
JP Morgan Asset Management
25.13M
1.45%
+5.11M
+25.51%
Dec 31, 2024
Norges Bank Investment Management (NBIM)
20.98M
1.21%
+626.72K
+3.08%
Dec 31, 2024
Wells Fargo Advisors
15.25M
0.88%
-105.40K
-0.69%
Dec 31, 2024
더 보기
관련 ETF
업데이트 시간: Mon, May 5
업데이트 시간: Mon, May 5
이름
비율
iShares U.S. Medical Devices ETF
17.41%
Polen Capital Global Growth ETF
5.18%
Goldman Sachs Future Health Care Equity ETF
4.98%
GMO US Quality ETF
4.9%
Invesco Pharmaceuticals ETF
4.86%
NYLI Healthy Hearts ETF
4.78%
AdvisorShares Focused Equity ETF
4.39%
Proshares Ultra Health Care
4.32%
Health Care Select Sector SPDR Fund
4.24%
iShares U.S. Healthcare ETF
4.15%
더 보기
iShares U.S. Medical Devices ETF
비율17.41%
Polen Capital Global Growth ETF
비율5.18%
Goldman Sachs Future Health Care Equity ETF
비율4.98%
GMO US Quality ETF
비율4.9%
Invesco Pharmaceuticals ETF
비율4.86%
NYLI Healthy Hearts ETF
비율4.78%
AdvisorShares Focused Equity ETF
비율4.39%
Proshares Ultra Health Care
비율4.32%
Health Care Select Sector SPDR Fund
비율4.24%
iShares U.S. Healthcare ETF
비율4.15%
주식 배당금
지난 5년 동안 총 16.46B USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
Dec 13, 2024
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
Sep 21, 2023
ABT.NB Final Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 09, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 17, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Dec 09, 2022
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 15, 2022
ABT.NB Final Cash Dividend of gross USD 0.47 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
더 보기
주식 분할
날짜
유형
비율
데이터 없음
날짜
유형
비율
데이터 없음
tradingkey.logo
tradingkey.logo
당일 거래 데이터는 Refinitiv에서 제공하며, 이용 약관이 적용됩니다. 역사적 및 현재 종가 데이터는 Refinitiv에서 제공합니다. 모든 시세는 현지 거래소 시간 기준입니다. 미국 주식 시세의 실시간 마지막 거래 데이터는 Nasdaq을 통해 보고된 거래만 반영됩니다. 당일 거래 데이터는 최소 15분 지연되거나 거래소 요구 사항에 따라 다를 수 있습니다.
* 참고자료, 분석 및 트레이딩 전략은 제3자 제공업체인 Trading Central에서 제공하며, 분석가의 독립적인 평가와 판단에 기반한 시각으로, 투자자의 투자 목표와 재정 상황은 고려되지 않습니다.
위험 경고: 저희 웹사이트와 모바일 앱은 특정 투자 상품에 대한 일반적인 정보만을 제공합니다. Finsights는 재정적 조언이나 투자 상품에 대한 추천을 제공하지 않으며, 이러한 정보 제공이 Finsights가 금융 조언이나 추천을 제공하는 것으로 해석되어서는 안 됩니다.
투자 상품은 투자 원금 손실을 포함한 상당한 투자 위험에 노출되어 있으며, 모든 사람에게 적합하지 않을 수 있습니다. 투자 상품의 과거 성과는 미래 성과를 보장하지 않습니다.
Finsights는 제3자 광고주나 제휴사가 저희 웹사이트나 모바일 앱 또는 그 일부에 광고를 게재하거나 전달할 수 있도록 허용할 수 있으며, 사용자가 광고와 상호작용하는 방식에 따라 이들로부터 보상을 받을 수 있습니다.
© 저작권: FINSIGHTS MEDIA PTE. LTD. 모든 권리 보유